key: cord-0837449-e8az2cw3
authors: Hirotsu, Y.; Maejima, M.; Shibusawa, M.; Natori, Y.; Nagakubo, Y.; Hosaka, K.; Sueki, H.; Mochizuki, H.; Tsutsui, T.; Kakizaki, Y.; Miyashita, Y.; Omata, M.
title: Similar viral loads in Omicron infections regardless of vaccination status
date: 2022-04-19
journal: nan
DOI: 10.1101/2022.04.19.22274005
sha: a4e8c766d83b567573827452e949adb2a0c087ab
doc_id: 837449
cord_uid: e8az2cw3

Background Although SARS-CoV-2 booster vaccinations are underway, breakthrough infections with Omicron variants are occurring. This study analyzed associations between Omicron sublineage (BA.1.1 and BA.2) viral load and vaccination history. Methods Viral loads in nasopharyngeal swabs were evaluated by quantitative real-time PCR, and the virus strain was evaluated by whole-genome analysis or TaqMan assay. Results A total of 611 patients positive for an Omicron SARS-CoV-2 variant were included; 199 were unvaccinated, 370 had received two vaccine doses, and 42 had received three doses. Similar viral loads and Ct values of BA.1.1 and BA.2 were detected regardless of vaccination history. No correlations between age and BA.1.1 and BA.2 viral load were observed. Conclusion Omicron-infected patients who had received a third vaccine dose had viral loads similar to patients with two doses or who were unvaccinated.

The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 49 has caused an estimated 497 million cases of coronavirus disease 2019 and 50 6.18 million deaths worldwide. SARS-CoV-2 has acquired mutations throughout its evolution, 51 driving the emergence of new viral strains. To date, five variants of concern have been 52 designated by the World Health Organization: Alpha, Beta, Gamma, Delta, and Omicron. 53 Omicron emerged in South Africa in 2021 and has spread worldwide. Unlike other variants 54 of concern, the Omicron variant has approximately 30 mutations in its spike protein. Some 55 of its mutations (e.g., 69-70del, T95I, G142D/143-145del, K417N, T478K, N501Y, N655Y, 56 N679K, and P681H) are also present in the Alpha, Beta, Gamma, and/or Delta variants. 57

These mutations lead to increased transmissibility, increased viral binding affinity, and 58 increased immune escape [1] . 59

Several Omicron sublineages have been reported; BA.1 and BA.1.1 were initially 60 most prevalent, but BA.2 is now predominating. Antibody activity against BA.1/BA. 

We performed SARS-CoV-2 diagnostic testing on samples collected from January 75 10, 2022 to April 7, 2022. The following diagnostic testing platforms were used in this study: 76 COVID-19 reverse transcription-PCR performed in accordance with the protocol developed 77 by the National Institute of Infectious Diseases in Japan [9] , the FilmArray Respiratory Panel 78 2.1 test performed with the FilmArray Torch system (bioMérieux, Marcy-l'Etoile, France) [10], 79 the Xpert Xpress SARS-CoV-2 test performed on a Cepheid GeneXpert system (Cepheid, 80 Sunnyvale, CA, USA) [11] , and the Lumipulse antigen test performed on a LUMIPULSE 81 G600II system (Fujirebio, Inc., Tokyo, Japan) [12, 13] . All tests were conducted on material 82 obtained from nasopharyngeal swabs immersed in viral transport media (Copan, Murrieta, 83 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 CA, USA). 84 85

To detect SARS-CoV-2, we performed one-step RT-qPCR to amplify the 87 nucleocapsid (N) gene of SARS-CoV-2 as previously described [14] . The human 88 ribonuclease P protein subunit p30 (RPP30) gene was used as the internal positive control 89 

Whole-genome sequencing was conducted in accordance with a previously 99 described method using the nasopharyngeal swab samples collected from 100 SARS-CoV-2-positive patients. In brief, SARS-CoV-2 genomic RNA was 101 reverse-transcribed into cDNA and amplified using the Ion AmpliSeq SARS-CoV-2 102

Research Panel or the Ion AmpliSeq SARS-CoV-2 Insight Research Assay (Thermo Fisher 103 Scientific) on the Ion Torrent Genexus system in accordance with the manufacturer's 104 instructions [15] [16] [17] . The sequencing reads were processed and their quality assessed using 105

Genexus software with SARS-CoV-2 plugins. The sequencing reads were then mapped and 106 aligned using the torrent mapping alignment program. After initial mapping, a variant call 107 was performed using the Torrent Variant Caller. The COVID19AnnotateSnpEff plugin was 108 used to annotate the variants. Assembly was performed using Iterative Refinement 109

The viral clade and lineage classifications were conducted using Nextstrain [19] 

We used the pre-designed TaqMan SARS-CoV-2 Mutation Panel to detect 117 SARS-CoV-2 spike Δ69-70, G339D, L452R, and Q493R (Thermo Fisher Scientific) in 118 SARS-CoV-2-positive samples [22] . The TaqMan MGB probe for the wild-type allele was 119 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 labeled with VIC dye, and the probe for the variant allele was labeled with FAM dye. This 120

TaqMan probe system can detect both wild-type and variant sequences of SARS-CoV-2. 121

TaqPath 1-Step RT-qPCR Master Mix CG was used as master mix. Real-time PCR was 122 conducted on a Step-One Plus Real-Time PCR system (Thermo Fisher Scientific). 

To analyze whether vaccination history altered the viral load after infection with the 152 Omicron sublineages, we quantitatively assessed viral load in nasopharyngeal swabs by 153 RT-qPCR (Figure 1 ). In BA.1.1-infected individuals, the mean viral loads ± SD were 5.3 ± 154 1.4 (range: -0.9-7.8) in the unvaccinated group, 5.4 ± 1.5 (-0.3-7.7) in the two-dose group, 155 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 6 and 4.6 ± 1.7 (2.2-6.8) in the three-dose group, while they were 5.4 ± 1.6 (range: 1.0-7.7), 156 5.8 ± 1.5 (-0.4-8.2), and 5.5 ± 1.7 (0.5-7.9), respectively, in the BA.2-infected individuals 157 ( Figure 1A) . In BA.1.1-infected individuals, the mean cycle thresholds (Ct) ± SD were 20.5 ± 158 5.1 (range: 12-44) in the unvaccinated group, 20.2 ± 5.1 (12-38) in the two-dose group, and 159 22.5 ± 5.7 (15-31) in the three-dose group, while they were 19.9 ± 5.6 (range: 12-35), 18.4 160 ± 5.0 (11-37), and 19.9 ± 6.0 (12-38), respectively, in the BA.2-infected individuals (Figure  161 1B). No significant differences in viral load or Ct values were found among the groups with 162 different vaccination histories (p > 0.05, pairwise t-test with Holm correction). 163

We next analyzed whether the viral load after vaccination was correlated with age 164 (Figures 1C and 1D ). The rapid spread of the Omicron variant worldwide has led to its replacement of the 189 Delta variant [21] . Omicron has multiple mutations in the spike protein, raising concerns that 190 antibodies may be less effective than they were against the ancestral strain and other 191 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 variants of concern [23-25]. Booster vaccination can lower the risk of infection with Omicron, 192 but the protection weakens over time [4, 6] We thank all medical and ancillary hospital staff for their support. We also thank Katherine 209

Thieltges from Edanz (https://jp.edanz.com/ac) for editing a draft of this manuscript. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 

Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. 228 Nature Medicine

The Omicron 230 variant is highly resistant against antibody-mediated neutralization: Implications for control of the 231 COVID-19 pandemic

Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

Safety and 236 Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. The 243 Lancet

High rate of BA

BA.1.1 and BA.2 infection in triple vaccinated

Genetic Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan

Comparison of Automated SARS-CoV-2 Antigen Test for COVID-19 Infection with Quantitative 264

RT-PCR using 313 Nasopharyngeal Swabs Including from 7 Serially Followed Patients

Double-quencher probes improve detection 267 sensitivity toward Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a 268 reverse-transcription polymerase chain reaction (RT-PCR) assay

Detection of R.1 lineage severe acute respiratory syndrome 271 coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan. 272 PLOS Pathogens

Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring 274

K417T/E484K/N501Y mutations in Kofu

SARS-CoV-2 B.1.1.7 lineage rapidly spreads and replaces R.1 277 lineage in Japan: Serial and stationary observation in a community

Viral deep sequencing 280 needs an adaptive approach: IRMA, the iterative refinement meta-assembler

Nextstrain: 284 real-time tracking of pathogen evolution

A dynamic 288 nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Global initiative on sharing all influenza data -from vision 291 to reality

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 19, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022